Acetylation of MAT IIα represses tumour cell growth and is decreased in human hepatocellular cancer

Hong-Bin Yang1,*, Ying-Ying Xu1,*, Xiang-Ning Zhao1,2, Shao-Wu Zou2, Ye Zhang1, Min Zhang1, Jin-Tao Li3, Feng Ren1, Li-Ying Wang1 & Qun-Ying Lei1,3,4

Metabolic alteration is a hallmark of cancer. Dysregulation of methionine metabolism is implicated in human liver cancer. Methionine adenosyltransferase IIα (MAT IIα) is a key enzyme in the methionine cycle, catalysing the production of S-adenosylmethionine (SAM), a key methyl donor in cellular processes, and is associated with uncontrolled cell proliferation in cancer. Here we show that P300 acetylates MAT IIα at lysine residue 81 and destabilizes MAT IIα by promoting its ubiquitylation and subsequent proteasomal degradation. Conversely, histone deacetylase-3 deacetylates and stabilizes MAT IIα by preventing its proteasomal degradation. Folate deprivation upregulates K81 acetylation and destabilizes MAT IIα to moderate cell proliferation, whereas a single mutation at K81 reverses the proliferative disadvantage of cancer cells upon folate deprivation. Moreover, MAT IIα K81 acetylation is decreased in human hepatocellular cancer. Collectively, our study reveals a novel mechanism of MAT IIα regulation by acetylation and ubiquitylation, and a direct functional link of this regulation to cancer development.
Folate is essential for rapidly proliferating cells and plays a pivotal role in one-carbon metabolism. Its metabolic derivative tetrahydrofolate (FH4), known as the carrier of one-carbon units, is involved in de novo synthesis of thymidylate and purine, amino-acid inter-conversion and so on. Coupling with methionine cycle, which produces the major methyl donor S-adenosylmethionine (SAM), folate metabolism also presents methyl-groups to global methylation of macromolecules.

Methionine adenosyltransferase (MAT) is the key enzyme in methionine cycle, catalysing biosynthesis of SAM. In mammals, two distinct genes, MAT1A and MAT2A, encode two homologous catalytic subunits—α1 and α2, respectively. MAT1A mainly expresses in healthy hepatocytes. Its encoding product, the α1 subunits, assemble into two MAT isozymes, MAT III (dimer) and MAT I (tetramer). In contrast, MAT2A and its coding product, MAT II (dimer formed from α2 subunits), is widely expressed in all hepatic tissues at relatively low level under normal conditions, whereas overexpressed in various human epithelial tumours, including gastric, colon and liver cancer. Studies indicated that enhanced MAT2A expression boosts cancer cell proliferation and potentially promotes tumour development and progression. MAT2A, but not MAT1A, is found expressed in fetal liver, whereas healthy adult liver expresses mainly MAT1A. MAT expression is progressively switched from MAT2A to MAT1A during liver development, whereas is reversed to MAT2A again during liver malignant transformation. In addition, knockdown MAT2A dramatically suppresses tumour cell proliferation and induces cell cycle arrest and apoptosis.

MAT2A expression is regulated at both transcriptional and post-transcriptional levels. Sp1 (transcription factor: specificity protein 1), c-Myb (transcription activator: avian myeloblastosis viral oncogene), NF-κB (nuclear factor of kappa, enhancer in B cells) and AP-1 (adaptor-related protein complex 1) were identified as the trans-activating factors involved in MAT2A transcriptional upregulation. Tumour-necrosis factor-α (TNF-α) upregulates MAT2A via NF-κB and AP-1 (ref. 14). Moreover, histone acetylation, promoter methylation and mRNA stabilization were also reported to regulate MAT2A expression.

Although regulation of MAT2A expression was heavily studied at transcriptional and post-transcriptional levels, its post-translational regulation remains largely unknown. Covalent lysine acetylation has been identified as an evolutionarily conserved modification in metabolic enzymes, and plays critical roles in regulation of multiple enzymes. In this study, we demonstrate that MAT IIx protein is acetylated at lysine residue 81 in response to folate deprivation. Acetylation promotes MAT IIx ubiquitylation and its subsequent proteosomal degradation, inhibiting tumour cell proliferation. Our observations reveal a novel mechanism of MAT IIx upregulation in human cancers.

Results

MAT IIx is acetylated at lysine 81. Previous mass spectrometry (MS) analyses indicated that MAT IIx was potentially an acetylated protein (Supplementary Fig. 1a). To confirm the acetylation modification, pan acetyl-lysine antibody was used to detect the acetylation level of ectopically expressed MAT IIx. Result showed that MAT IIx was indeed acetylated in HEK293T and Chang’s cells (Fig. 1a). Furthermore, trichostatin A (TSA), an inhibitor of histone deacetylase HDAC family I, II and IV, increased the acetylation level of flag-MAT IIx approximately two- to threefold (Fig. 1a). Given that lysine (K) 81 is the only putative acetylation site identified in MAT IIx by MS (Fig. 1b and Supplementary Fig. 1a), and is evolutionarily conserved from D. melanogaster to mammals, we mutated K81 to arginine (R) and glutamine (Q) and found that both mutations resulted in a significant reduction in acetylation (Fig. 1c). Notably, TSA treatment dramatically increased the acetylation level of wild-type MAT IIx, but not K81R or K81Q mutant, indicating K81 might be the primary acetylation site of MAT IIx (Fig. 1c). To further confirm acetylation of K81, we generated a K81 site-specific antibody specifically targeting to acetylated K81 residue in MAT IIx (designated as ‘K81Ac antibody’ henceforth). Dot blotting assay was performed to characterize the specificity of this antibody and found that K81Ac antibody preferentially detected K81 acetylated, but not unmodified peptide (Fig. 1d). In addition, strong and specific signal of K81 acetylation was observed in ectopically expressed wild-type MAT IIx but not K81R mutant (Supplementary Fig. 1b). Further results showed that both MAT2A knockdown (Fig. 1e) and peptide blocking by K81 acetylated peptide (Fig. 1f) significantly reduced K81Ac signal, indicating a high specificity of this antibody to MAT IIx K81 acetylation. More importantly, with the help of this site-specific antibody, we detected enhanced K81 acetylation signal of endogenous MAT IIx in different cell lines upon TSA treatment (Fig. 1g). These results indicate that K81 is the major acetylation site of MAT IIx under the tested condition.

Folate decreases K81 acetylation and stabilizes MAT IIx. Folate’s metabolic derivative tetrahydrofolate plays an essential role in transferring one-carbon units. Restoration of methionine from homocysteine in methionine cycle greatly depends on methyl-groups (one type of one-carbon units) presented from folate metabolism. Therefore, methionine cycle is tightly related to folate availability and one-carbon unit metabolism. As serine hydroxymethyl transferase and glycine cleavage are two major sources of one-carbon units, methionine cycle is also related to serine and glycine metabolisms. To determine whether K81 acetylation of MAT IIx is dynamically regulated by serine, glycine or folate in vivo, we cultured HEK293T cells in medium containing these metabolites with different concentrations and found that K81 acetylation level of MAT IIx increased as concentrations of folate decreased (Fig. 2a, upper panel). In contrast to this, serine and glycine showed no effect on MAT IIx K81 acetylation (data not shown). More interestingly, steady-state level of MAT IIx protein decreased as concentrations of folate decreased (Fig. 2a, lower panel). Similar results were obtained in human hepatocellular carcinoma cell line—Huh7 (Supplementary Fig. 2a). These results indicate a potential inverse correlation between MAT IIx acetylation and protein levels in response to folate concentration.

K81 acetylation promotes MAT IIx degradation. To determine whether downregulation of MAT IIx protein by folate occurs at transcriptional level, quantitative reverse transcription–PCR was performed. Results showed that folate treatment had no effect on MAT IIx mRNA level (Fig. 2b), indicating that folate regulates MAT IIx protein mainly at the post-transcriptional level. To determine whether acetylation induced MAT IIx degradation is mediated by proteosomal pathway, we treated HEK293T cells with proteasome inhibitor MG132 and found both TSA and folate deprivation induced decrease in MAT IIx protein can be readily restored by MG132 (Fig. 2c and Supplementary Fig. 2b), suggesting K81 acetylation in response to TSA or folate deprivation might target MAT IIx protein to proteosomal degradation. The fact that MAT IIx was accumulated in HEK293T, H1299 and U937 cells after treated with MG132 further supported this
speculation (Supplementary Fig. 2c). In addition, TSA treatment combined with protein synthesis inhibitor cycloheximide (CHX) dramatically decreased the half-life of endogenous MAT IIα (Supplementary Fig. 2d). These results indicate that TSA- and folate deprivation-induced MAT IIα protein degradation is proteasomal dependent. To further test the possibility that TSA or folate deprivation promotes MAT IIα degradation via K81 acetylation, half-lives of wild-type, K81R and K81Q MAT IIα were determined by CHX chase experiment. Wild-type MAT IIα, but not the mutants, was found to display a shortened half-life under folate-deprived condition (Fig. 2d), indicating proteasomal degradation of MAT IIα might be related to K81 acetylation. In addition, we employed ubiquitylation ladder assay and observed a significant increase in wild-type MAT IIα ubiquitylation in the presence of TSA or upon folate deprivation, whereas ubiquitylation of K81R mutation was mostly blocked and no longer respond to either TSA or folate deprivation (Fig. 2e,f). Consistently, we found MG132 could block TSA- or folate deprivation-induced MAT IIα destabilization (Fig. 2g and Supplementary Fig. 2e). Collectively, these results demonstrate that K81 acetylation of MAT IIα promotes its degradation via ubiquitylation-mediated proteasomal degradation.

**UBR4 targets MAT IIα for degradation.** Three types of enzymes are required in the process of ubiquitylation: ubiquitin-activating enzymes (E1s), ubiquitin-conjugating enzymes (E2s) and ubiquitin-ligases (E3s), among which, only E3s define the target specificity of ubiquitylation reaction. To further investigate the mechanism of TSA- or folate deprivation-induced MAT IIα
proteasomal degradation, we established an HEK293-derived cell
line stably expressing both streptavidin-binding protein and flag-
tagged MAT IIα, cultured upon folate deprivation and purified
MAT IIα protein using tandem affinity purification to identify its
E3 ligase via MS. Among the consistently identified interacting
proteins, we identified UBR4 (ubiquitin protein ligase E3 com-
ponent n-recognition 4, belongs to the zinc finger E3 ligase family)
as a putative E3 ligase for MAT IIα. To verify whether UBR4 is an
E3 ligase for MAT IIα, we overexpressed UBR4 (D) (expressing a
truncated form of UBR4 protein, with substrate-binding and
catalytic domains only) in HEK293T cells and found a significant
drop in MAT IIα protein, which was totally reversed by adding
MG132 to the culture medium (Fig. 3a). Furthermore, knocking
down UBR4 expression by three independent short interfering
RNAs (siRNAs) could instantly block folate deprivation-induced
MAT IIα degradation (Fig. 3b). Consistently, CHX chase

ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms7973
www.nature.com/naturecommunications
experiment showed that UBR4 knockdown could totally block the decreased half-life of MAT I12 upon folate deprivation (Fig. 3c). Moreover, UBR4 knockdown increases MAT I12 protein level and its acetylation level (Supplementary Fig. 3, left panel). The efficacy of UBR4 knockdown was validated by quantitative PCR (qPCR; Supplementary Fig. 3, right panel). In addition, we performed ubiquitin ladder experiment to visualize ubiquitylation. Consistent with previous findings, polyubiquitylation signal of MAT I12 was detected upon folate deprivation (Fig. 3d), whereas HA-tagged ubiquitin could no longer be detected at high molecular weight after knocking down UBR4 expression (for quantification of UBR4 mRNA level, please refer to Fig. 3d). Collectively, these results verify UBR4 as an E3 ligase participating in polyubiquitylation-mediated proteasomal degradation of MAT I12.

**P300 acetylates MAT I12 at K81.** To identify the acetyl-transferease responsible for MAT I12 acetylation, we co-transfected four HATs (histone acetyl-transferases), P300 (E1A binding protein), PCAF (P300/CBP-associated factor, also known as K (lysine) acetyl-transferase 2B, KAT2B), CBP (CREB-binding protein) and GCN5 (KAT2A), individually with MAT2A into HEK293T cells, and found P300 overexpression increased MAT I12 acetylation, whereas others did not (Fig. 4a). In addition, overexpression of P300 increased endogenous K81 acetylation of MAT I12 (Fig. 4b). To further verify whether P300 acetylates MAT I12 at K81, we designed experiment shown in Supplementary Fig. 4, and proved that P300 overexpression only increases acetylation of wild-type MAT I12, but not the K81R/Q mutant. Conversely, knocking down P300 by RNA interference significantly reduced K81 acetylation of endogenous MAT I12 (Fig. 4c). P300 decreased MAT I12 protein level in a dose-dependent manner (Fig. 4d), whereas P300 knockdown rescued folate deprivation-induced MAT I12 destabilization (Fig. 4e). Moreover, we found folate-deprivation increased the interaction between endogenous MAT I12 and P300 (Fig. 4f), and this interaction was further verified by glutathione S-transferase (GST) pull-down (Fig. 5f). To further examine the hypothesis that P300 is the acetyl-transferase of MAT I12, in vitro acetylation assay was conducted. As shown in Fig. 4g, recombinant P300 instantly acetylated MAT I12 at K81. Collectively, our results demonstrate that P300 is the acetyl-transferase responsible for MAT I12 acetylation at K81.

**HDAC3 deacetylates MAT I12 at K81.** According to the previous results that TSA, an inhibitor of type I, II and IV HDACs, increased K81 acetylation of MAT I12, we postulated that HDACs might be involved in MAT I12 deacetylation. We co-expressed HDAC1-7 individually with MAT I12, and found that over-expression of HDAC3, but not other tested HDACs, decreased the acetylation level of ectopically expressed MAT I12 (Fig. 5a and Supplementary Fig. 5). Thereafter, we overexpressed HDAC3 in HEK293T cells, and found a decrease in K81 acetylation of endogenous MAT I12 (Fig. 5b). Notably, HDAC3 knockdown decreased the steady protein level of MAT I12 (Fig. 5c). Furthermore, we found HDAC3 knockdown led to the destabilization of MAT I12 (Fig. 5d), further supported that deacetylation stabilizes MAT I12. Previous study by Katoh et al. identified HDAC3 as a putative MAT I12-interacting protein by MS analysis16. To verify this interaction between HDAC3 and MAT I12, we performed co-immunoprecipitation (co-IP) experiment and found that interaction indeed exists between these two proteins, and the interaction could be further enhanced in the presence of folate (Fig. 5e). Similarly, GST pull-down was performed to further verify this interaction (Fig. 5f). Taken together, HDAC3 is the deacetylase for MAT I12 K81 acetylation.

**K81 mutants promote tumour growth in vitro and in vivo.** Given MAT I12 overexpression was previously implicated to promote cancer cell proliferation and cancer progression17,18, we next examined the effect of MAT I12 acetylation on cell proliferation and tumour growth. To this end, we generated stable cell lines in HepG2 cells in which endogenous MAT I12 was knocked down by short hairpin RNA (shRNA; targeting 3′-untranslated region of MAT2A gene) and the shRNA-resistant MAT I12 wild-type, K81Q or K81R (each contains only coding sequence of wild-type or mutated MAT2A gene) was stably expressed. Western blotting analysis demonstrated that the endogenous MAT I12 was effectively knocked down and that wild-type, K81Q or K81R mutants were expressed at levels similar to that of the endogenous MAT I12 (Fig. 6a). Direct cell count and MTT assays were both applied to monitor cell proliferation velocities of wild-type or K81 mutant stable cells under normal or folate-deprived conditions. MAT2A knockdown instantly caused growth arrest in HepG2 stable cell line (Supplementary Fig. 6a). HepG2 cells expressing K81R and K81Q mutant stable cells were found proliferating significantly faster than cells expressing wild-type MAT I12 upon folate deprivation, whereas under normal condition, no significant difference in proliferating velocity was detected (Fig. 6b and Supplementary Fig. 6b). As MAT I12 catalyses the production of main methyl donor SAM, and SAM is converted to SAH (S-adenosyl-homocysteine) after the methyltransferation reaction, we then investigated SAM/SAH levels.

**Figure 2 | Folate decreases K81 acetylation and stabilizes MAT I12.** (a) Folate deprivation increases K81 acetylation of MAT I12 and decreases its protein level. HEK293T cells were cultured in medium containing folate of different concentrations as indicated for 48 h. Western blotting was used to determine MAT I12 protein and K81 acetylation levels. (b) Folate-deprivation has no effect on MAT2A mRNA level. MAT2A mRNA was determined by qPCR and normalized against β-actin. Error bars represent ± s.d. of triplicate experiments. The two-tailed Student’s t-test was used. NS denotes no significance. (c) MG132 rescues the decrease in MAT I12 protein induced by folate deprivation. HEK293T cells were cultured as indicated and treated with either dimethylsulphoxide (DMSO; solvent) or 10 μM MG132 for 6 h. Cell lysates were analysed by western blotting. (d) Folate deprivation exclusively shortens the half-life of wild-type MAT I12, but not K81R or K81Q mutant. HEK293 stable cell lines expressing wild-type MAT I12, or K81R/K81Q mutants were cultured in folate-deprived condition for 48 h, CHX (10 μg/ml) treatment was applied for different time course before harvest. MAT I12 protein levels were determined by western blotting (left panel). The right panel showcases relative protein amounts of different groups. Error bars represent ± s.d. of triplicate experiments. The two-tailed Student’s t-test was used. **P < 0.01; ***P < 0.001. (e) K81R mutation blocks MAT I12 ubiquitylation induced by TSA. HEK293T cells were transfected with the indicated plasmids. After TSA and MG132 treatment as indicated, ubiquitylation of purified flag-MAT I12 proteins were determined. (f) Folate deprivation promotes ubiquitylation of wild-type MAT I12 but not K81R mutant. HEK293T cells were transfected as indicated. Ubiquitylation of flag-MAT I12 protein was determined by western blotting. (g) MG132 stabilizes MAT I12 upon folate deprivation. HEK293T cells were cultured under normal or folate-deprived condition, followed by CHX and MG132 treatment. Cell lysates were directly subjected to western blotting (left panel). The right panel showcases relative protein amounts of different groups. Error bars represent ± s.d. of triplicate experiments. The two-tailed Student’s t-test was used. **P < 0.01; ***P < 0.001.
ratio in different stable cell lines and found that folate deprivation significantly decreased SAM/SAH ratio in wild-type but not in K81R/Q mutant-expressing cells (Supplementary Fig. 6c). As a result, global methylation in wild-type-expressing cells cultured upon folate deprivation was found decreased, compared with that of the mutant-expressing cells grew under the same condition (Supplementary Fig. 6d).

To determine folate’s effect on MAT IIz K81 acetylation in tumour growth, we performed xenograft experiments using HepG2 stable cell lines referred previously. Nude mice were subcutaneously injected with HepG2 stable cells and fed with folate-free diet. Tumour growth was continuously monitored thereafter. Measurement of the widths and lengths of tumours demonstrated that HepG2 cells expressing K81R or K81Q
Figure 4 | P300 acetylates MAT IIα. (a) Overexpression of P300, not other HATs, increases acetylation of exogenous MAT IIα. HEK293T cells were transfected as indicated and acetylation of flag-MAT IIα was determined using Pan-Ac antibody. (b) Overexpression of P300 increases K81 acetylation of endogenous MAT IIα. HEK293T cells were transfected with flag-P300 and K81 acetylation of MAT IIα was determined using K81Ac antibody. (c) P300 knockdown decreases MAT IIα K81 acetylation. HEK293T cells were transfected with siP300 or control and MAT IIα acetylation levels were determined by western blotting. (d) P300 decreases protein levels of MAT IIα. Flag-P300 was transfected in declined doses into HEK293T cells and cell lysates were measured by western blotting. (e) P300 knockdown increases MAT IIα stability. HEK293T cells were transfected with siP300 or control and cultured under folate-deprived condition before CHX was added and treated for indicated durations. Levels of endogenous MAT IIα protein were determined by western blotting and normalized against β-actin (left panel). The right panel showcases relative protein amounts of different groups. Error bars represent ± s.d. of triplicate experiments. The two-tailed Student’s t-test was used. *P<0.05; **P<0.01; ***P<0.001. (f) Folate-deprivation enhances MAT IIα-P300 interaction. HEK293T cells were transfected with flag-tagged MAT IIα and cultured in normal or folate-deprived conditions. The interaction between flag-MAT IIα and endogenous P300 was determined by co-IP followed by western blotting. (g) P300 acetylates MAT IIα at K81 in vitro. Ectopically expressed GST-MAT IIα from BL21 E. coli was purified through GST antibody-conjugated beads and incubated with P300 (immunoprecipitation-purified and eluted). K81 acetylation levels were analysed using K81Ac antibody and normalized against GST-MAT IIα.

mutants displayed a growth rate significantly faster than those expressing wild-type MAT IIα upon folate-deprived dietary (Fig. 6c and Supplementary Fig. 6e). At the time of harvesting, mice injected with cells expressing K81R/K81Q mutants developed larger tumours than those injected with cells expressing wild-type MAT IIα (Fig. 6d). In addition, levels of MAT IIα protein in stable cell lines and xenograft tumours derived from stable cell lines were assessed by western blotting. protein levels of K81R and K81Q mutants were found indeed higher than that of the wild-type MAT IIα (Fig. 6e). Collectively, K81 mutants stabilize MAT IIα and promote tumour cell growth upon folate-deprivation both in vitro and in vivo.
K81 acetylation is decreased and inversely correlated with MAT IIα in human hepatocellular cancer. MAT IIα over-expression is implicated in human hepatocellular carcinoma (HCC). The finding that K81Q or K81R mutant promotes HepG2 cell proliferation prompted us to examine K81 acetylation in human hepatocellular cancers. We collected 80 pairs of primary human hepatocellular cancer samples with adjacent normal tissues for direct immunoblotting. Results showed that, compared with the matched normal liver tissues, 40 pairs of samples showed a significant increase of total MAT IIα protein in cancerous tissues (Fig. 6f and Supplementary Fig. 6f). To further examine the correlation between K81 acetylation and MAT IIα protein, we determined MAT IIα K81 acetylation in these 40 pairs of samples, and found that 32 pairs of samples showed relatively higher levels of K81 acetylation in the tumour tissues than that of the matched normal tissues (Fig. 6f and Supplementary Fig. 6g). Furthermore, we found that HDAC3 expression was increased in 19 out 32 HCC samples (Supplementary Fig. 6f). The tumour sample analyses demonstrate that MAT IIα protein levels are elevated in hepatocellular cancers, and K81 acetylation inversely correlates with the elevated MAT IIα protein. These data also indicate an application prospect of using MAT IIα and K81 acetylation as potential biomarkers for hepatocellular cancer diagnosis.
**Figure a:** HepG2 stable cell

| shMAT2A | Flag-MAT IIα | MAT IIα/β-actin ratio | Flag-MAT IIα | MAT IIα/β-actin ratio | Flag/β-actin ratio | Flag/β-actin ratio |
|---------|--------------|------------------------|--------------|------------------------|-------------------|-------------------|
| -       | +            | 1.0 0.9 1.0 1.1        | +            | 1.0 0.9 1.0 1.1        | 1.0 1.0 1.0 1.0   | 1.0 1.0 1.0 1.0   |
| -       | +            | 55 kDa                 | +            | 55 kDa                 | 55 kDa            | 55 kDa            |
| -       | +            | 40 kDa                 | +            | 40 kDa                 | 40 kDa            | 40 kDa            |

**Figure b:** HepG2 cell count

**Figure c:** Folate-deprived diet

**Figure d:** Folate-deprived diet

**Figure e:** HepG2 stable cell

**Figure g:** Folate

**Figure f:** #H50 #H53 #H60 #H153023 #H153107 #H153255 #H153288 #H153471

| K81Ac/β-actin ratio | N | C     | N | C     | N | C     | N | C     | N | C     | N | C     |
|---------------------|---|-------|---|-------|---|-------|---|-------|---|-------|---|-------|
| 1.0                  | 0.1| 1.0   | 0.2| 1.0   | 1.0| 0.3   | 1.0| 0.1   | 1.0| 0.1   | 1.0| 0.1   |
| 55 kDa               |   |       |   |       |   |       |   |       |   |       |   |       |

**Figure h:** Balanced cell proliferation

**Figure i:** Increased cell proliferation

---

**Note:** The figures and tables contain data on various experimental conditions and outcomes, including changes in cell number, tumor mass, and protein expression levels under folate-deprived and normal conditions.
Discussion
Dysregulation of cellular metabolism is a hallmark of cancer. Besides elevated glycolysis, increased lipogenesis and so on, dysregulation of amino-acid metabolism is also implicated in cancer. Imbalanced methionine metabolism in human liver cancer has been known for at least 60 years. Liver can be considered as the body's SAM factory, and MAT is the key enzyme catalysing biosynthesis of SAM. Overexpression of MAT2A is common in various types of cancer, whereas knocking down MAT2A gene expression causes cell cycle arrest and apoptosis in cancer cells. Our study reveals a novel mechanism of MAT IIa regulation by acetylation and ubiquitination in response to folate concentration (Fig. 6g) and provides a new mechanistic insight in MAT IIa upregulation in cancer.

Upregulation of MAT IIa in cancer is in part due to MAT2A overexpression regulated by alerted gene transcription or mRNA stability. In this study, we report two post-translational modifications of MAT IIa. We propose that MAT IIa acetylation modulated by folate concentration and consequent ubiquitination play crucial roles in MAT IIa stability control. When folate is sufficient, MAT IIa is stabilized via HDAC3 deacetylation and subsequent inhibition of ubiquitination. Accumulation of MAT IIa therefore enhances tumour growth. Conversely, when folate is deprived, P300 acetylates MAT IIa at K81. Acetylation therefore promotes UBR4-mediated MAT IIa ubiquitination, leading to its proteasomal degradation and reduced cell growth.

Folate is needed in large quantities in rapidly proliferating cells. Folate uptake is increased in several types of solid human cancers including ovarian, endometrial, colorectal, kidney, lung and breast carcinomas. Anti-folate drugs have long been approved for treating cancers. Therefore, one may expect an important role for folate in MAT IIa regulation.

Indeed, folate-induced MAT IIa stabilization results in an increase in SAM production (Supplementary Fig. 6c). We speculate that SAM accumulation would possibly cause dysregulations of oncogenes and tumour-suppressor genes via affecting global methylation, eventually leading to tumorigenesis and cancer development. In addition, the fact that stabilization of MAT IIa by K81 mutations significantly promotes cancer cell proliferation and in vivo tumour growth indicates a critical role of MAT IIa acetylation in coordinating folate availability and the regulation of cell growth and tumorigenesis. It also suggests a possibility that promoting MAT IIa acetylation may merit exploration as a target for cancer therapy. Notably, the observation that MAT IIa is overexpressed in hepatocellular cancer tissues, whereas K81 acetylation is significantly decreased indicates a pivotal role of MAT IIa acetylation regulation in hepatocellular cancer development.

Methods
Cell culture and treatment. Cells were all purchased from American Type Culture Collection and cultured in DMEM/high-glucose medium (HyClone) supplemented with 10% fetal bovine serum (HyClone), 1% penicillin and streptomycin at 37°C, in a humidified atmosphere containing 5% CO2. Standard RPMI-1640 and RPMI-1640 without folate were purchased from Life Technologies. Inc. (GIBCO). For folate-deprivation treatment, cells were cultured in the medium containing different amounts of folate for at least 2 weeks. For TSA, MG132, CHX treatment, see descriptions in figure legends, respectively.

Immunoprecipitation and western blotting. Cells were lysed in 0.3% Nonidet P40 buffer (150 mM NaCl, 50 mM Tris-HCl, pH 7.5) containing inhibitors (1 mM phenylmethylsulphonyl fluoride, 1 μg/ml of aprotinin, 1 μg/ml of leupeptin, 1 μg/ml of pepstatin, 1 mM Na3VO4, 1 mM NaF; 30 μM TSA and 15 mM NAM, all in their final concentrations). Cell debris were removed by centrifugation at 4°C, 13,000 r.p.m. for 15 min, and lysates were incubated for 3 h at 4°C with anti-flag M2 agarose (Sigma). The immunoprecipitates were washed three times with 0.3% Nonidet P40 buffer before boiled and analysed by western blotting according to the standard methods. The following primary antibodies were commercially obtained: Flag (Sigma, with 1:10,000 working dilution), HA (Santa Cruz, with 1:1,000 working dilution), β-actin (Sigma, with 1:10,000 working dilution), P300 (Santa Cruz, with 1:1,000 working dilution), MAT IIa (Santa Cruz, with 1:1,000 working dilution), acetylated-lysine (Cell Signaling, with 1:1,000 working dilution). Anti-body specific to MAT IIa K81Ac was prepared commercially from immunizing rabbits at Shanghai Genepharma Inc. (with 12,000 working dilution). Images from western blotting have been cropped for presentation. Full-size images are presented in Supplementary Fig. 7.

Ubiquitin ladder assay. Ubiquitin ladder assay was performed as previously described. Thirty-six hours after transfection, cells were collected and lysed in 1% SDS buffer (50 mM Tris-HCl (pH 7.5), 0.5 mM EDTA, 1 mM dithiothreitol) with inhibitors and boiled for 10 min. Before immunoprecipitation, lysates were diluted ten-fold with 0.3% Nonidet P40 buffer. Ubiquitination was determined by western blotting.

siRNA transfection and RNA interference. Downregulation of UBR4, P300 and HDAC3 was performed by RNA interference. Synthetic siRNA oligonucleotides were obtained commercially from Shanghai GenePharma Co. Ltd. Sequences of effective sequences are as follows:

\[
\begin{align*}
\text{siUBR4-1} & : 5'-\text{CGUCGCCAGAGUCGUCCUAAAdTdT-3'} \\
\text{siUBR4-2} & : 5'-\text{GCUGUGUAGUGAAUUGUGAAAdTdT-3'} \\
\text{siUBR4-3} & : 5'-\text{GGACAAUCACCGUAAUAdTdT-3'} \\
\text{sif300-1} & : 5'-\text{UGACACAGGCGGCGUGAGAdTdT-3'} \\
\text{sif300-2} & : 5'-\text{AACAGACGAGGCUCCGUAAAdTdT-3'} \\
\text{siHDAC3} & : 5'-\text{CAGCGCAGAACUAAUUUGAdTdT-3'}
\end{align*}
\]

All siRNA transfections were performed as described in Lipofectamine 2000 (Invitrogen) standard protocol. The knockdown efficiency was verified by western blotting or qPCR.

Knocking down and putting back stable cell lines. Flag-tagged human wild type, K81R and K81Q mutants of MAT2A were cloned into the retroviral vector (pQCXII) and co-transfected into HEK293T cells together with vectors expressing gag and vsvg genes (from vesicular stomatitis virus G). Retroviral supernatants were harvested by filtration (0.45 μm filters) 48 h after initial plasmid transfection and mixed with polybrene (8 μg/ml) as final concentration to increase the infection efficiency before applied to HepG2 cells. HepG2 cells were infected with the prepared virus for 12 h and screened by hygromycin (350 μg/ml) as final concentration for at least 2 weeks. pMKO-shMAT2A and pMKO-shVEC were

Figure 6 | K81 mutations promote tumour cell growth in vitro and in vivo. (a) Verification of HepG2 stable cell lines. Knockdown efficiency and re-expression levels of wild-type or K81R/Q mutants were determined by western blotting. (b) K81R and K81Q mutations reverse the proliferative disadvantage of HepG2 cells upon folate deprivation. HepG2 stable cell characterized in a were cultured in normal or folate-deprived medium. Direct cell count was performed every 24 h after seeding. Error bars represent cell numbers ± s.d. for triplicate experiments. The two-tailed Student’s t-test was used. **P<0.01; ***P<0.001. (c,d) K81R and K81Q mutants promote xenograft tumour growth. Subcutaneous xenograft experiment was performed in nude mice using HepG2 stable cells. Major and minor diameters of tumours were measured and tumour volumes were calculated. The two-tailed Student’s t-test was used. *P<0.05; **P<0.01; ***P<0.001; NS denotes no significance. (c) 25 days after injection, tumours were dissected, photographed and weighted. The two-tailed Student’s t-test was used. *P<0.05; **P<0.01; ***P<0.001; NS denotes no significance. (d) The expression of wild-type, K81R and K81Q MAT IIa in xenografts. Whole-cell lysates were prepared from either original HepG2 stable cell lines or xenograft tumours, followed by western blotting analysis. (f) The hepatocellular cancer clinical samples show an inverse correlation between MAT IIa protein and K81 acetylation. Human hepatocellular cancer samples each paired with cancerous tissue (designated as C) and adjacent normal tissue (designated as N) were lysed and directly subjected to western blotting. Only eight pairs of samples showcasing inverse correlation are shown. For more samples, please refer to Supplementary Fig. 6f. (g) Working model. By enhancing MAT IIa acetylation by P300 and UBR4, folate deprivation stimulates both MAT IIa K81 acetylation and ubiquitination, resulting in its proteasomal degradation. Folate stabilizes MAT IIa by dissociating MAT IIa-P300-UBR4 complex, and promoting MAT IIa-HDAC3 interaction. Accumulated MAT IIa α protein facilitates rapid cell proliferation and, therefore, promotes tumour growth.
constructed as Short Hairpin RNA vector. shRNA constructs including shMAT2A employed two effective sequences targeting 3'-untranslated region as follows: 5'-GGCTAAGTGGATCCATGTAACCT-3'; 5'-GTAAGTGGGGAATCCTATC-3'. HepG2 stable cells expressing flag-tagged wild type, K81R or K81Q of MAT I' were infected with pMKO-shMAT2A and pMKO-shVEC retrovirus. MAT I' knockdown efficiency of positive clones was determined after 2 weeks of drug selection (puromycin, 5 μg/mL as final concentration).

GST pull-down assay. BL21 E. coli transformed with pGEX-GST-MAT I' plasmid was induced (or not induced) by isopropyl-β-D-thiogalactoside (0.1 mM as final concentration) at 20°C for 12 h. Protein was then purified through GST antibody-conjugated beads. Beads were then added to HIEK293T cell lysate (lysed by 0.3% Nonidet P40 buffer), and mixed at 4°C overnight. Non-induced group was used as a negative control. Beads were subsequently harvested through centrifugation and washed four times by 0.3% Nonidet P40 buffer before boiled by 1× SDS–polyacrylamide gel electrophoresis loading buffer and subjected to western blotting.

In vitro acetylation assay. Ectopically expressed MAT I' from BL21 E. coli was purified through GST antibody-conjugated beads and incubated with P300 (immunoprecipitation-purified and eluted) in histone acetyl-transferase (HAT) assay buffer (purchased from Millipore), supplemented with acetyl-coenzyme A (10 μM as final concentration). Reaction was conducted under 30°C for 1 h with continuous shaking. After adding 5× SDS–polyacrylamide gel electrophoresis loading buffer and boiled, samples were analysed by western blotting.

Cell proliferation analysis. 5× 10⁴ HepG2 stable cells were seeded in triplicate in each well of six-well plate, and cultured in normal or folate-deprived medium. Cell numbers were counted every day over a 5-day period via haemacytometer counting method. For MTT (3-(4,5-dimethyl-2-thiazoyl-2,5-diphenyl-2H-tetrazolium bromide)) assays, 2× 10⁴ HepG2 stable cells were seeded in quintuplicate in each well of 96-well plate. Standard methods were performed to track the cell proliferation.

Xenograft analysis. The procedures related to animal studies were approved by the Ethics Committee of the Institutes of Biomedical Sciences, Fudan University. Rodent diet without folate was purchased from Research Diets, Inc. Nude mice (nu/nu, six-week-old males) were fed with folate-deprived diet for 1 week, followed by continuous shaking. After adding 5× SDS–polyacrylamide gel electrophoresis loading buffer and boiled, samples were analysed by western blotting.

Hepatocarcinoma cancer samples. Hepatocarcinoma cancer samples were obtained from the 10th People’s Hospital, Shanghai (Tongji University Affiliated), with written consents from all investigated patients. The procedures related to human subjects were approved by the Ethics Committee of the Institutes of Biomedical Sciences, Fudan University. Direct immunoblotting was performed as mentioned above.

SAM and SAH quantification. SAM and SAH quantification were performed as previously described25. Cells were harvested and weighed. The cell pellets were added with 0.4 M perchloric acid; mixed vigorously and centrifuged. Supernatants were adjusted to pH 5–7 with 2.5 M K₂HPO₄ and kept on ice for 15 min to precipitate potassium perchlorate. Samples were centrifuged twice and supernatants were analysed by liquid chromatography-tandem mass spectrometry.

Methylated DNA quantification. Genomic DNA was prepared using a DNA isolation kit (Beyotime). A methylated DNA quantification kit (Colorimetric; Abnova) was used to detect methylated DNA.

Statistical analysis. Two-tailed Student’s t-tests were used for all comparisons, including qPCR analysis. All values included in the figures represent mean ± s.d. Error bars represent ± s.d. for triplicate experiments. The statistical significance is indicated as asterisks (*). Two-sided P value of <0.05 was considered to be statistically significant (*P<0.05, **P<0.01, ***P<0.001).

References
1. Stover, P. J. & Field, M. S. Trafficking of intracellular folates. Adv. Nutr. 2, 325–331 (2011).
2. Koth, M. et al. Consensus nomenclature for the mammalian methionine adenosyltransferase genes and gene products. Trends Genet. 13, 51–52 (1997).
3. Lu, S. C. & Mato, J. M. S-adenosylmethionine in liver health, injury, and cancer. Physiol. Rev. 92, 1515–1542 (2012).
4. Chen, H. et al. Role of methionine adenosyltransferase 2A and S-adenosylmethionine in mitogen-induced growth of human colon cancer cells. Gastroenterology 143, 207–218 (2007).
5. Liu, Q. et al. The X protein of hepatitis B virus inhibits apoptosis in hepatoma cells through enhancing the methionine adenosyltransferase 2A gene expression and reducing S-adenosylmethionine production. J. Biol. Chem. 286, 17168–17180 (2011).
6. Yang, H., Li, T. W., Peng, J., Mato, J. M. & Lu, S. C. Insulin-like growth factor 1 activator methionine adenosyltransferase 2A transcription by multiple pathways in human colon cancer cells. J. Biol. Chem. 436, 507–516 (2011).
7. Zhang, T. et al. Overexpression of methionine adenosyltransferase II alpha (MAT2A) in gastric cancer and induction of cell cycle arrest and apoptosis in SGC-7901 cells by shRNA-mediated silencing of MAT2A gene. Acta Histochem. 115, 48–55 (2013).
8. Halim, A. B., LeGros, L., Chamberlin, M. E., Geller, A. & Koth, M. Regulation of the human MAT2B gene encoding the catalytic alpha 2 subunit of methionine adenosyltransferase, MAT II. J. Biol. Chem. 276, 24918–24924 (2001).
9. Liu, Q. et al. Silencing MAT2A gene by RNA interference inhibited cell growth and induced apoptosis in human hepatoma cells. Hepatol. Res. 37, 376–388 (2007).
10. Wang, Q. et al. Inhibition of hepatocellular carcinoma MAT2A and MAT2beta gene expressions by single and dual small interfering RNA. J. Exp. Clin. Cancer Res. 27, 72 (2008).
11. Ramani, K. et al. Changes in the expression of methionine adenosyltransferase genes and S-adenosylmethionine homeostasis during hepatic stellate cell activation. Hepatology 51, 986–995 (2010).
12. Yang, H., Huang, Z. Z., Wang, J. & Lu, S. C. The role of c-Myc and Sp1 in the up-regulation of methionine adenosyltransferase 2A gene expression in human hepatocellular carcinoma. FASEB J 15, 1507–1516 (2001).
13. Yang, H. et al. Induction of human methionine adenosyltransferase 2A expression by tumor necrosis factor alpha. Role of NF-kappa B and AP-1. J. Biol. Chem. 278, 50887–50896 (2003).
14. Frau, M. et al. Role of transcriptional and posttranscriptional regulation of methionine adenosyltransferases in liver cancer progression. Hepatology 56, 165–172 (2012).
15. Choudhary, C. et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325, 834–840 (2009).
16. Liu, R. et al. Acetylation stabilizes ATP-citrate lyase to promote lipid biosynthesis and tumor growth. Mol. Cell 51, 506–518 (2013).
17. Zhao, S. et al. Regulation of cellular metabolism by protein lysine acetylation. Science 327, 1000–1004 (2010).
18. Katoh, Y. et al. Methionine adenosyltransferase II serves as a transcriptional corepressor of Maf oncprotein. Mol. Cell 41, 554–566 (2011).
19. Allard, J. E. et al. Overexpression of folate binding protein is associated with shortened progression-free survival in uterine adenocarcinomas. Gynecol. Oncol. 107, 52–57 (2007).
20. Hartmann, L. C. et al. Folate receptor overexpression is associated with poor outcome in breast cancer. Int. J. Cancer 121, 938–942 (2007).
21. O’Sahnnassy, D. J. et al. Folate receptor alpha expression in lung cancer: diagnostic and prognostic significance. Oncotarget 3, 414–425 (2012).
22. Wang, Y. C. & Chiang, E. P. Low-dose methotrexate inhibits methionine S-adenosyltransferase in vitro and in vivo. Mol. Med. 18, 432–432 (2012).
23. Jiang, W. et al. Acetylation regulates gluconeogenesis by promoting PEPC1K degradation via recruiting the UBR5 ubiquitin ligase. Mol. Cell 43, 33–44 (2011).
24. Zhang, W. et al. Fluorinated N,N-dialkylaminomethylbenzene repress colon cancer by targeting methionine S-adenosyltransferase 2A. ACS Chem. Biol. 8, 796–803 (2013).

Acknowledgements We thank Lei Zhang and Guoquan Yan from Biomedical Core Facility, Fudan University, for technical support. This work was supported by MOST (2015CB910401, 2011CB910601), NSFC (Grant No. 81430057, 81225016), Shanghai Key basic research program (12JC1401100), ‘100 Talents’ Program of Shanghai Health (Grant No. XBR2011041), Scholar of ‘Dawn’ Program of Shanghai Education Commission, the Youth Science and Technology Talent by MOST and Shanghai Outstanding Academic Leader (Grant No. 13XD1400600) to Q.-Y.L.

Author contributions H.-B.Y., Y.-Y.X. and L.-Y.W. performed the experiments, analysed the data and co-wrote the manuscript. Y.Z., M.Z. and F.R. contributed to the data analysis. J.-T.L., constructed pGEX-GST-MAT I’ plasmid and contributed data analysis. S.-W.Z. and L.-Y.W. contributed to study of human hepatocarcinoma cancer samples. Y.-Y.X. and S. C. & Mato, J. M. S-adenosylmethionine in liver health, injury, and cancer. Physiol. Rev. 92, 1515–1542 (2012).
S.-W.Z. supervised the project. Q.-Y.L. conceived the idea, designed and supervised the study, analysed the data and co-wrote the manuscript.

Additional information
Supplementary Information accompanies this paper at http://www.nature.com/naturecommunications

Competing financial interests: The authors declare no competing financial interests.

Reprints and permission information is available online at http://npg.nature.com/reprintsandpermissions/

How to cite this article: Yang, H.-B. et al. Acetylation of MAT IIα represses tumour cell growth and is decreased in human hepatocellular cancer. Nat. Commun. 6:6973 doi: 10.1038/ncomms7973 (2015).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/